Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Industrifonden in connection with the investment round in Amra
Mandate

Vinge advises Industrifonden in connection with the investment round in Amra

January 24, 2017

The investment round was led by Pfizer Venture Investments and VC Novo Seeds together with the existing investor Industrifonden.

AMRA has developed a method for measuring body fat and muscle mass using a magnetic camera. The company’s aim is to assess the risk of serious illness based upon the patient’s body profile. The investment round facilitates an international establishment and an expanded network among leading pharmaceutical companies.

Vinge’s team consisted of Johan Larsson and Johan Mattsson.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026